SAGE News and Press, Sage Therapeutics Inc. From 04/01/22

Wall Street ended a two-day losing streak on Friday, as a late-day push allowed the major U.S. equity indices to finish a choppy session with gains. Amid a solid jobs report and an inverted yield curve, investors considered whether the rally that marked most of late March could resume in the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the last trading day of the week and that means it’s time to get into the pre-market stock movers for Friday! Source: oneinchpunch/Shutterstock.com We’re seeing loads of earnings reports, a...

Sage Therapeutics (NASDAQ:SAGE) said a mid-stage study of SAGE-718 showed improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). In the phase 2 trial, dubbed...

Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cogniti...

The following slide deck was published by Sage Therapeutics, Inc. in conjunction with this event. For further details see: Sage Therapeutics (SAGE) presents at 2022 Stifel CNS Days - Slideshow

Sage is well funded by Biogen. However, lead candidate SAGE-217 has not come up with strong MDD data. I continue to sit on the fence. For further details see: Sage Therapeutics: Well-Funded But Uninspiring Data

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at 4:00pm ET. A live webcast of the presen...

Gainers: OraSure Technologies (NASDAQ:OSUR) +5%, Iovance Biotherapeutics (NASDAQ:IOVA) +4%, Marqeta (NASDAQ:MQ) +3%, Chimerix (NASDAQ:CMRX) +3%, Ribbon Communications (NASDAQ:RBBN) +3%. Losers: Incannex Healthcare (NASDAQ:IXHL) -10%, CarParts.com (NASDAQ:PRTS) -5%, Eargo (NASDAQ:EAR) -5%...

Sage Therapeutics (NASDAQ:SAGE) said that data from a phase 2 trial showed SAGE-718 was associated with improvements on multiple tests of functioning and learning and memory in patients with mild cognitive impairment (MCI) due to Parkinson’s disease (PD) In the PARADIGM study (Part A),...

Data Presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and effic...